Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
European Journal of Preventive Cardiology · 11.05.2024 · 31 (7) · 903-914
DOI: 10.1093/eurjpc/zwae032 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Preventive Cardiology, online erschienen am 22.01.2024. Verfasst von Pia R Kamstrup und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Copenhagen University Hospital-Herlev and Gentofte, Borgmester Ib Juuls Vej 73, 2730 Herlev, Denmark. Hauptthemen laut MEDLINE: Lipoprotein(a), Cardiovascular Diseases. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma.
Abstract (Originalsprache)
Lipoprotein(a) (Lp(a)) is a genetically determined causal risk factor for cardiovascular disease including coronary heart disease, peripheral arterial disease, ischaemic stroke, and calcific aortic valve stenosis. Clinical trials of specific and potent Lp(a)-lowering drugs are currently underway. However, in clinical practice, widespread assessment of Lp(a) is still lacking despite several guideline recommendations to measure Lp(a) at least once in a lifetime in all adults to identify those at high or very high risk due to elevated levels. The present review provides an overview of key findings from observational and genetic Lp(a) studies, highlights the main challenges in observational Lp(a) studies, and proposes a minimum set of requirements to enhance the quality and harmonize the collection of Lp(a)-related data. Adherence to the recommendations set forth in the present manuscript is intended to enhance the quality of future observational Lp(a) studies, to better define thresholds for increased risk, and to better inform clinical trial design. The recommendations can also potentially assist in the interpretation and generalization of clinical trial findings, to improve care of patients with elevated Lp(a) and optimize treatment and prevention of cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, Copenhagen University Hospital-Herlev and Gentofte, Borgmester Ib Juuls Vej 73, 2730 Herlev, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Academic Health Science Network North East and North Cumbria (AHSN), Room 2.13, Biomedical Research Building, The Campus for Ageing and Vitality, Nun's Moor Road, Newcastle, NE4 5PL.
- Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Hindenburgdamm 30, Berlin 12203, Germany.
- DZHK (German Centre for Cardiovascular Research) partner Site Berlin, Berlin 12203, Germany.
ORCID-Profile: Pia R Kamstrup
Förderung
- Novartis Pharma
Zitieren
APA
Kamstrup, P. R., Neely, R. D. G., Nissen, S., Landmesser, U., Haghikia, A., Costa-Scharplatz, M., Abbas, C., & Nordestgaard, B. G. (2024). Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research. European Journal of Preventive Cardiology, 31(7), 903-914. https://doi.org/10.1093/eurjpc/zwae032
Vancouver
Kamstrup PR, Neely RDG, Nissen S, Landmesser U, Haghikia A, Costa-Scharplatz M, et al. Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research. European Journal of Preventive Cardiology. 2024;31(7):903-914. doi:10.1093/eurjpc/zwae032
BibTeX
@article{Kamstrup2024,
author = {Kamstrup, Pia R and Neely, R Dermot G and Nissen, Steven and Landmesser, Ulf and Haghikia, Arash and Costa-Scharplatz, Madlaina and Abbas, Cheryl and Nordestgaard, Børge G},
title = {Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research},
journal = {European Journal of Preventive Cardiology},
year = {2024},
volume = {31},
number = {7},
pages = {903--914},
doi = {10.1093/eurjpc/zwae032}
}
EUVIMED